Giving NOAC treatment at myocardial injury after non-cardiac surgery lowers major vascular complications
ACC 2018 The MANAGE trial studied the effect of dabigatran in patients with myocardial injury after non-cardiac surgery. After a mean of 16 months follow-up, a relative risk reduction of 28% in major vascular complications was seen.
This 3-minute education provides a summary of just presented scientific data, recorded during the ACC 2018. The objective is to provide a brief commentary and potential implications of these findings.
P.J. Devereaux is director of the division of Cardiology, at McMaster University, in Hamilton, ON, Canada
This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenters and do not necessarily reflect the views of PACE-cme.
The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.
Share this page with your colleagues and friends: